Abstract:Abstract BACKGROUND: Extranodal natural killer/T-cell lymphoma, nasal type, (ENKTCL) is a rare and aggressive peripheral T-cell lymphoma associated with Epstein-Barr virus infection of neoplastic cells. The current standard-of-care for patients (pts) with localized disease is combined modality with radiation and systemic chemotherapy, while advanced disease is treated with asparaginase-based combination chemotherapy or chemoradiation. To date, there is limited real-world data regarding the clinico-pathological markers, survival patterns, and long-term outcomes ENKTCL in the United States. METHODS: We conducted a retrospective study of pts with ENKTCL. We reviewed clinical variables, pathological characteristics, treatment patterns and outcomes. Patients who were treated/referred to our instituition from 2009-2020 were included in the analysis. We excluded cases with missing treatment and/or no follow up information. Fisher's exact test or Chi-square test was used to evaluate the association between two categorical variables. Kaplan-Meier method was used to estimate the time-to-event endpoints including progression free survival (PFS) and overall survival (OS). RESULTS: A total of 69 patients met diagnostic criteria and were included in this retrospective analysis. Forty (60%) patients were <60 years of age at diagnosis with median age of 53 years (range 13-94); 38 (57%) were men. Thirty-five (50%) patients had early-stage, 28 (40%) advanced-stage disease among whom all but one had stage 4 disease, and 6 (10%) were unknown. Extranodal sites involved were cutaneous/ subcutaneous (n=16), CNS (n=5) and bone/ bone marrow (n=5). Of the cases with CD30 testing done, 54% (20/36) were positive. In early-stage disease, 10 pts received either radiation alone (n=4) or chemotherapy alone (n=6), while 24 received combined modality therapy. Only 15 patients with advanced-stage disease received frontline asparaginase based therapy. Five patients received CHOP based therapy all prior to 2014. Among the 53 patients evaluable for response, the overall response (OR) to first line treatment was 67.92% (95% CI: 53.68 ~ 80.08%) with complete response (CR) rate of 66.04% (95% CI: 51.73 ~ 78.48%). In those with early stage, 77% had a CR, whereas only 47 % with advanced disease had CR to frontline treatment (p=0.0327). Eight patients with advanced-stage disease underwent consolidation high dose chemotherapy and autologous stem cell transplant, with 2 relapses post-therapy. The the median PFS to frontline treatment was 12.48 months (95% CI: 7.23-38.63), for stages I/II 19.15 months, and for stages III/IV 7.23 months . The PFS rate at 2 years was 35% (95% CI: 0.24-0.51) for the entire cohort, 46% (95% CI: 0.3-0.71) for stage I/II, and 21% (95% CI: 0.09-0.47) for stage III/ IV (p=0.0264) (Figure 1A). Extranodal involvement of the skin / subcutaneous tissue was associated with worse outcomes (Figures 1B and C), with a median PFS to frontline treatment at 3.52 months versus 14.22 months (P=0.0025), and a 2-year PFS of 14% (95% CI: 0.04-0.52). The median OS (Figure 1D) for the entire cohort was 33.94 months (95%CI 14.22 - NA), with OS at 2 years (Figure 1A) of 54% (95% CI: 0.42 -0.71) for the whole cohort, 72% (95% CI: 0.56 -0.92) for stage I/II and 33% (95% CI: 0.18 - 0.6) for stage III/ IV (p=0.0055). The most common second line regimen was SMILE (n=7, 5CRs and 1PR). Novel therapies included brentuximab vedotin (n=4), pembrolizumab (n=6), and EBV-directed T cell infusion (n=5). Analysis of molecular predictive markers, clinical correlates and toxicity data is currently ongoing and will be presented at the meeting. CONCLUSION: ENKTCL has poor prognosis especially in advanced stages. In this large single institution cohort, we evaluated the clinical and treatment patterns of this disease over a 12-year period. Our cohort was characterized by younger age and early stage. Higher response rates and improved survival were seen in those with early stage. In advanced stage; the presence of skin/ subcutaneous involvement was identified as a high-risk feature for worse survival. Furthermore, this trend was maintained for PFS and OS for those with advanced stages and skin/ subcutaneous involvement. A better understanding of targetable pathways and a unified treatment approach is needed to improve the outcomes for patients with high-risk features. Figure 1 Figure 1. Disclosures Huen: Rhizen: Research Funding; Elorac: Research Funding; Kyowa Kirin: Research Funding; Tillium: Research Funding; Innate: Research Funding; Galderma: Research Funding; Miragen: Research Funding. Ahmed: Seagen: Research Funding; Tessa Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; Xencor: Research Funding. Steiner: BMS: Research Funding; Seattle Genetics: Research Funding; Rafael Pharmaceuticals: Research Funding. Chihara: Astrazeneca: Honoraria. Jain: Lilly: Consultancy; kite: Consultancy. Nastoupil: Caribou Biosciences: Research Funding; Novartis: Honoraria, Research Funding; Epizyme: Honoraria, Research Funding; MorphoSys: Honoraria; Genentech: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Gilead/Kite: Honoraria, Research Funding; Bayer: Honoraria; Pfizer: Honoraria, Research Funding; ADC Therapeutics: Honoraria; TG Therapeutics: Honoraria, Research Funding; Bristol Myers Squibb/Celgene: Honoraria, Research Funding; IGM Biosciences: Research Funding; Takeda: Honoraria, Other: DSMC, Research Funding; Denovo Pharma: Other: DSMC. Pinnix: Merck Inc: Research Funding. Neelapu: Kite, a Gilead Company, Merck, Bristol Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Cell Medica/Kuur, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr, Unum Therapeutics and Bluebird Bio: Honoraria; Takeda Pharmaceuticals and related to cell therapy: Patents & Royalties; Kite, a Gilead Company, Bristol Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics (Cogent Biosciences), Allogene, Precision BioSciences, Acerta and Adicet Bio: Research Funding; Kite, a Gilead Company, Merck, Bristol Myers Squibb, Novartis, Celgene, Pfizer, Allogene, Kuur, Incyte, Precision BioSciences, Legend, Adicet Bio, Calibr, and Unum Therapeutics: Other: personal fees. Flowers: 4D: Research Funding; TG Therapeutics: Research Funding; Adaptimmune: Research Funding; Morphosys: Research Funding; AbbVie: Consultancy, Research Funding; Cellectis: Research Funding; Pharmacyclics/Janssen: Consultancy; Karyopharm: Consultancy; Gilead: Consultancy, Research Funding; Kite: Research Funding; Ziopharm: Research Funding; Iovance: Research Funding; Nektar: Research Funding; Spectrum: Consultancy; SeaGen: Consultancy; Celgene: Consultancy, Research Funding; Biopharma: Consultancy; Bayer: Consultancy, Research Funding; Epizyme, Inc.: Consultancy; Denovo: Consultancy; Janssen: Research Funding; Takeda: Research Funding; Burroughs Wellcome Fund: Research Funding; Genmab: Consultancy; BeiGene: Consultancy; Amgen: Research Funding; Xencor: Research Funding; Novartis: Research Funding; Genentech/Roche: Consultancy, Research Funding; National Cancer Institute: Research Funding; EMD: Research Funding; Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research: Research Funding; Sanofi: Research Funding; Acerta: Research Funding; Eastern Cooperative Oncology Group: Research Funding; Allogene: Research Funding; Pfizer: Research Funding; Guardant: Research Funding; Pharmacyclics: Research Funding. Hosing: Nkarta Therapeutics: Membership on an entity's Board of Directors or advisory committees. Wang: OMI: Honoraria; Celgene: Research Funding; BGICS: Honoraria; Moffit Cancer Center: Honoraria; Genentech: Consultancy; Miltenyi Biomedicine GmbH: Consultancy, Honoraria; Bayer Healthcare: Consultancy; Imedex: Honoraria; Juno: Consultancy, Research Funding; The First Afflicted Hospital of Zhejiang University: Honoraria; Dava Oncology: Honoraria; Oncternal: Consultancy, Research Funding; Scripps: Honoraria; InnoCare: Consultancy, Research Funding; DTRM Biopharma (Cayman) Limited: Consultancy; AstraZeneca: Consultancy, Honoraria, Research Funding; Clinical Care Options: Honoraria; Mumbai Hematology Group: Honoraria; BeiGene: Consultancy, Honoraria, Research Funding; Epizyme: Consultancy, Honoraria; CAHON: Honoraria; Hebei Cancer Prevention Federation: Honoraria; Chinese Medical Association: Honoraria; Loxo Oncology: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; VelosBio: Consultancy, Research Funding; Molecular Templates: Research Funding; Lilly: Research Funding; BioInvent: Research Funding; CStone: Consultancy; Newbridge Pharmaceuticals: Honoraria; Physicians Education Resources (PER): Honoraria; Kite Pharma: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Anticancer Association: Honoraria; Acerta Pharma: Consultancy, Honoraria, Research Funding. Vega: i3Health, Elsevier, America Registry of Pathology, Congressionally Directed Medical Research Program, and the Society of Hematology Oncology: Research Funding; CRISPR Therapeutics and Geron: Research Funding. Iyer: CRISPRX: Research Funding; Seattle Genetics: Research Funding; Rhizen: Research Funding; Merck: Research Funding; Legend: Research Funding; Innate: Research Funding; Spectrum: Research Funding; Trillium: Research Funding; Astra Zeneca: Research Funding; Yingli: Research Funding; Cyclacel: Research Funding.

Abstract:We have recently shown that bone marrow (BM) RNA profiles stratify patients with acute myeloid leukemia (AML) into immune-infiltrated and immune-depleted subtypes and that type I/II interferon (IFN)-related gene signatures associate with complete response to flotetuzumab (FLZ), an investigational CD123×CD3 bispecific DART molecule. Within the AML tumor microenvironment CD8+ T cells exhibit features of immune exhaustion and senescence (IES). IES are dysfunctional states driven by metabolic alterations in the tumor microenvironment (TME) and emerging targets for cancer immunotherapy. The aim of the current study was to determine whether IES predicts response of relapsed-refractory (R/R) AML to FLZ in the CP-MGD006-01 clinical trial. Based on prior knowledge and gene set enrichment analysis, we derived a 61-gene IES signature score from RNA-sequencing datasets (TCGA and Beat-AML Master Trial; 162 and 281 patients, respectively). The immunotherapy cohort included 139 BM samples from 71 patients with R/R AML treated with FLZ at the RP2D of 500 ng/kg/day (NCT02152956). BM samples were collected at time of study entry (n=71; n=66 with response data) and longitudinally post-cycle (PC)1 (n=40), PC2 (n=18), PC3 and 4 (n=4) and end of treatment (n=6). AML status at study entry was classified as primary induction failure (PIF, defined as lack of response to at least 2 induction treatment cycles), and early (ER) or late relapse (LR), defined as complete remission (CR) of <6-month or ≥6-month duration, respectively. Overall response rate (ORR), collectively complete response, was defined as <5% BM blasts (CR, CRh, CRi or MLFS), and partial response (PR) was defined as >50% decrease or decrease to 5-25% BM blasts. RNAs were profiled on the PanCancer IO 360TM gene expression panel on the nCounter® platform. Formalin-fixed paraffin embedded BM biopsies were profiled using the human IO protein and RNA panels on the GeoMx® digital spatial profiler (DSP). The 61 genes in the IES signature included T/NK-cell markers (granzymes, CD8A, KLRD1, KLRK1), immune checkpoints (ICOS, CTLA4, EOMES), IFNG and IFN-stimulated genes (CXCR6, IFIH1, IL10RA, GBP1), and were enriched in KEGG pathways related to Th1/Th2 differentiation, TCR signaling, cytokine-cytokine receptor interaction, NK-mediated cytotoxicity and CD28 costimulation (false discovery rate<0.001 for all; Fig. 1A). Unsupervised hierarchical clustering of gene expression allowed the identification of BM samples with high, intermediate and low IES scores at time of study enrollment (Fig. 1B). Ninety-five percent (18/19) of patients in the IEShigh cluster had PIF/ER AML, congruent with prior studies showing enhanced immune infiltration and IFN signaling in the TME of patients with PIF. Notably, ORR to FLZ (complete response, n=18 or PR, n=5) were documented in 11/19 (58%), 10/32 (31.2%) and 2/15 (13.3%) of patients in the IEShigh, IESint and IESlow cluster, respectively (Fig. 1B). The IES signature score was significantly higher at baseline in patients who responded to FLZ compared with non-responders (P=0.0052; Fig. 1C). High-dimensional flow cytometry of sequential BM samples collected at time of study entry and PC1 of FLZ showed the on-treatment upregulation on both CD4 and CD8 T cells of early activation markers CD69 and CD38 (but not the late activation marker HLA-DR), as well as immune checkpoints LAG3 and Tim-3, and proliferation marker Ki-67, indicating FLZ-mediated modulation of the immune TME. To determine the variation in co-expression of T-cell markers associated with FLZ treatment, we also measured lymphocytes obtained from 21 BM samples prior to and post-FLZ using an unsupervised multivariate analysis. Qualitative comparisons of the principal component analysis (PCA) showed distinct phenotypic changes in BM samples post-treatment (Fig. 1D). Characterization of BM biopsies using GeoMx DSP showed distinct T-cell clustering in responders (Fig. 1E). PCA showed enhanced CD45, CD3, CD4 and PDL1 in situ RNA/protein expression (fold change 1.96, 2.83, 3.32, 4.7, respectively, P<0.05 for all) at PC1 of FLZ in OR versus non-responders (Fig. 1F). In conclusion, features of IES were associated with response to FLZ. T-cell functional rejuvenation by FLZ could benefit patients with R/R AML by counteracting pre-existing immune dysfunction. Figure Disclosures Church: NanoString Technologies, Inc.: Current Employment. Uy:Pfizer: Consultancy; Agios: Consultancy; Genentech: Consultancy; Jazz Pharmaceuticals: Consultancy; Astellas Pharma: Honoraria; Daiichi Sankyo: Consultancy. Emadi:Genentech: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; NewLink Genetics: Research Funding; Jazz Pharmaceuticals: Research Funding; KinaRx: Other: co-founder and scientific advisor; Servier: Membership on an entity's Board of Directors or advisory committees. Walter:Aptevo Therapeutics: Research Funding. Foster:Bellicum Pharmaceuticals: Research Funding; Macrogenics: Consultancy, Research Funding; Daiichi Sankyo: Consultancy. Arellano:Cephalon Oncology: Research Funding; Hanmi: Research Funding; Gilead Sciences, Inc: Consultancy, Membership on an entity's Board of Directors or advisory committees. Wieduwilt:Amgen: Research Funding; Leadiant: Research Funding; Merck: Research Funding; Shire: Research Funding; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; Macrogeneics: Research Funding. Michaelis:Jazz Pharmaceuticals: Research Funding. Stiff:Kite, a Gilead Company: Research Funding; Gamida Cell: Research Funding; Atara: Research Funding; Unum: Research Funding; Delta-Fly: Research Funding; Macrogenics: Research Funding; Amgen: Research Funding. Advani:Takeda: Research Funding; Immunogen: Research Funding; Glycomimetics: Consultancy, Other: Steering committee/ honoraria, Research Funding; Macrogenics: Research Funding; Abbvie: Research Funding; Seattle Genetics: Other: Advisory board/ honoraria, Research Funding; Amgen: Consultancy, Other: steering committee/ honoraria, Research Funding; Kite: Other: Advisory board/ honoraria; Pfizer: Honoraria, Research Funding; Novartis: Consultancy, Other: advisory board; OBI: Research Funding. Wermke:MacroGenics: Honoraria. Erba:AbbVie, Daiichi Sankyo, Forma, ImmunoGen, Jazz Pharmaceuticals, MacroGenics, Novartis, PTC: Research Funding; AbbVie, Agios, Celgene, Incyte, Jazz Pharmaceuticals, and Novartis: Speakers Bureau; AbbVie, Agios, Amgen, Astellas, Celgene, Daiichi Sankyo, Glycomimetics, ImmunoGen, Incyte, Jazz Pharmaceuticals, MacroGenics, Novartis, and Pfizer: Consultancy; Glycomimetics: Other: member of Scientific Steering Committee; Celgene: Other: chair of the Scientific Steering Committee; Covance (AbbVie): Other: chair of the Independent Review Committee. Ravandi:Orsenix: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria; Macrogenics: Research Funding; Xencor: Consultancy, Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria. Topp:Amgen, KITE, Novartis, Regeneron, Roche: Consultancy; Amgen, Boehringer Ingelheim, KITE, Regeneron, Roche: Research Funding. Muth:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Kaminker:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Gojo:Amgen: Research Funding; Merck: Research Funding; Amphivena: Research Funding; Genentech: Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees. Luznik:AbbVie: Consultancy; WindMil Therapeutics: Patents & Royalties: Patent holder; Merck: Research Funding, Speakers Bureau; Genentech: Research Funding. DiPersio:Magenta Therapeutics: Membership on an entity's Board of Directors or advisory committees. Davidson-Moncada:Macrogenics: Current Employment. Rutella:NanoString Technologies, Inc.: Research Funding; MacroGenics, Inc.: Research Funding; Kura Oncology: Research Funding.

CD70 is a Potential Target Biomarker in Peripheral T‐cell Lymphomas

CD70 Expression in Mature T-Cell Lymphomas

Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

Abstract 1827: CD70 is a novel therapeutic target for EGFR mutant NSCLC with acquired, EMT-associated EGFR TKI resistance

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

CD70, a novel target of CAR T-cell therapy for gliomas

Why are Higher CD34+ Cell Doses Associated with Improved Outcomes among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors – But Not for High-Risk Neuroblastoma?

Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models

A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma

A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-Oncology (IO)

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series

Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia